相关实验视频
Updated: May 7, 2025

07:27
Olfactory Assays for Mouse Models of Neurodegenerative Disease
Published on: August 25, 2014
21.9K
老龄化和阿尔茨海默病中的嗅觉缺陷 - - 聚焦抑制性内部神经元
Kaoutar Elhabbari1, Siran Sireci1, Markus Rothermel1
1Institute of Physiology, RG Neurophysiology and Optogenetics, Medical Faculty, Otto-von-Guericke-University, Magdeburg, Germany.
Frontiers in neuroscience
|December 31, 2024
概括
老龄化和阿尔茨海默氏症中的嗅觉缺陷
科学领域:
- 神经科学是一个神经科学.
- 神经生物学 神经生物学 神经生物学
- 老年学是一门学科.
背景情况:
- 认知功能与衰老和阿尔茨海默病 (AD) 中的嗅觉性能有关.
- 嗅觉缺陷在健康老龄化和AD进展中都被观察到.
- 了解嗅觉缺陷的原因对于早期诊断和干预至关重要.
研究的目的:
- 审查阻断性内部神经元在嗅球 (OB) 和初级嗅皮层中的作用.
- 为了比较健康的衰老和AD之间的嗅觉区域内核神经元组成的变化.
- 了解内部神经元如何影响嗅觉行为和缺陷.
主要方法:
- 对OB和嗅觉皮层中抑制性内部神经元的当前知识的综述.
- 在健康衰老和AD之间,在不同嗅觉大脑区域的内部神经元变化的比较.
- 对内部神经元群体在衰老和AD中的脆弱性进行分析.
主要成果:
- 衰老和AD都表现出激发/抑制平衡的改变,这表明抑制网络功能减少.
- 阿尔茨海默病与嗅觉区域的GABAergic内部神经元的显著损失有关,类似于海马和皮质区域.
- 衰老并没有在嗅觉GABAergic内部神经元中表现出这种明显的细胞损失.
- 在AD中,特定的内部神经元群体,特别是体静止素阳性细胞,在所有嗅觉区域都更容易受到伤害.
结论:
- 嗅觉GABAergic内部神经元的病理生理变化有助于AD的嗅觉缺陷.
- 内部神经元的脆弱性因亚型而异,索马托斯塔丁阳性细胞受到影响最大.
- 对抑制性内部神经元的进一步研究对于理解和治疗衰老和AD中的嗅觉功能障碍至关重要.
相关概念视频
Olfactory Receptors: Location and Structure
8.5K
The process of olfaction, also known as the sense of smell, is a sophisticated chemical response system. The specialized sensory neurons that facilitate this process, known as olfactory receptor neurons, are situated in an upper segment of the nasal cavity, known as the olfactory epithelium. Olfactory sensory neurons are bipolar, with their dendrites extending from the epithelium's apex into the mucus that lines the nasal cavity. Airborne molecules, when inhaled, traverse the olfactory...
8.5K
Olfaction
44.0K
The sense of smell is achieved through the activities of the olfactory system. It starts when an airborne odorant enters the nasal cavity and reaches olfactory epithelium (OE). The OE is protected by a thin layer of mucus, which also serves the purpose of dissolving more complex compounds into simpler chemical odorants. The size of the OE and the density of sensory neurons varies among species; in humans, the OE is only about 9-10 cm2.
The olfactory receptors are embedded in the cilia of the...
The olfactory receptors are embedded in the cilia of the...
44.0K
Alzheimer's Disease: Overview
311
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
311
Role of Neurotransmitters in Memory
276
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
276
Physiology of Smell and Olfactory Pathway
7.5K
Humans detect odors with the help of specialized cells located in the upper part of the nasal cavity, called olfactory receptor neurons (ORNs). ORNs possess hair-like structures called cilia, which are receptive to sensations from the inhaled air. When an odorant molecule binds to a specific receptor on the cell of the cilia, it leads to a series of events that ultimately cause the ORN to send electrical signals to the olfactory bulb in the brain through the olfactory nerves.
The olfactory...
The olfactory...
7.5K
Alzheimer's Disease: Treatment
125
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
125

